Integra LifeSciences vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Integra LifeSciences Holdings (IART)

Q3 202615 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

August 202615 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

Latest15 Jul – 5 Oct 2026

▲2▼1

Flood cuts guidance, but Q2 beat and SurgiMend ramp offer hope

Cincinnati flood forces guidance cut July flooding at Integra's Cincinnati facility disrupted operations, prompting the company to slash full-year 2026 revenue and earnings guidance below Wall Street's expectations. This is the main reason the stock is under pressure, as it signals near-term supply problems and lost sales.
This is the biggest new negative event that directly explains why IART is moving right now.
Q2 earnings beat with margin expansion Integra reported second-quarter adjusted EPS of $0.56, up 24.4% from a year ago and ahead of guidance, while gross and EBITDA margins expanded. This shows the underlying business is still profitable and executing well, which supports the stock despite the flood setback.
It provides the positive counterweight to the flood news and shows operational strength.
SurgiMend relaunch production begins Integra started making SurgiMend at its Braintree facility and is building inventory for a phased fourth-quarter 2026 relaunch. While the product won't add much this year, it sets up a potential recovery in 2027, giving investors a reason to look past current troubles.
It is a new operational milestone that could drive future growth and investor optimism.
Refinancing with $600M loan Integra plans a $600 million seven-year secured loan to pay down debt and cover fees. This could ease near-term debt worries but also adds interest costs, and the company's leverage remains above its target range, so the market's reaction is mixed.
It is a new capital markets action that affects the company's financial risk and flexibility.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.